[Criteria for the optimal use of interleukin-6 receptor blockers in patients with COVID-19].

Tat'yana S Kruglova Darya S Fomina Nataliya G Poteshkina N F Frolova Irina P Beloglazova Zinaida Yu Mutovina Inna V Samsonova E A Kovalevskaja A I Zagrebneva S A Serdotetckova Anton A Chernov Mar'yana A Lysenko

Published in: Terapevticheskii arkhiv (2021)

IL-6 receptor blockers should be administered to patients hospitalized with severe COVID-19 before the development of hyperinflammatory reactions. The optimal "therapeutic window" is 78 days of illness.

Keyphrases

end stage renal disease
coronavirus disease
sars cov
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
early onset